SEC Tracker
Get the app
OKUR · XBRL financial data

OnKure Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (OKUR's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024†Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025†Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Revenue—————year only——————
Research and development13,62217,604*4,94259090437,359*13,01212,61311,91510,720*11,70712,611
General and administrative7,2667,402*4,6225,7743,760(3,564)*3,9883,7113,5863,405*3,9084,288
Total operating expenses20,88825,006*9,5646,3644,66433,795*17,00016,32415,50114,125*15,61516,899
Operating income (loss)(20,888)(25,006)*(9,564)(6,364)(4,664)(33,795)*(17,000)(16,324)(15,501)(14,125)*(15,615)(16,899)
Other income (expense)1,6921,452*1,1381,003972———————
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)(19,196)(23,554)*(8,426)(5,361)(3,692)(17,442)(15,925)(15,390)(14,699)(13,503)(15,157)(15,346)
Earnings per share, basic USD per share(0.57)(0.70)*(0.25)(0.16)(1.10)—(1.19)(1.14)(1.09)—(1.11)(0.31)
Earnings per share, diluted USD per share(0.57)(0.70)*(0.25)(0.16)(1.10)—(1.19)(1.14)(1.09)—(1.11)(0.31)
Weighted average shares, basic thousands of shares33,80833,519*33,42133,4213,343—13,42413,50913,53113,597*13,67549,869
Weighted average shares, diluted thousands of shares33,80833,519*33,42133,4213,343—13,42413,50913,53113,597*13,67549,869
  • † Share count changed about 1/10 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 4x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 3x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (OKUR's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024†Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025†Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Cash and cash equivalents11,73727,63220,37535,97060,689110,76196,66183,37470,33159,050192,106166,502
Short-term investments113,87775,33162,46040,70415,979———————
Marketable securities—————————0—9,884
Prepaid and other current assets3,1583,6591,0921,3163312,2421,5111,1781,1951,7895,3761,291
Total current assets128,772106,62283,92777,99076,999113,00398,17284,55271,52660,839197,482177,677
Property and equipment, net52913410281591,025925821720618519435
Right-of-use asset1,006599546493440770676581485387288840
Total assets130,388107,43684,63978,71777,645114,90799,88286,07072,83562,117198,694179,353
Accounts payable2,4738,717676642372,9682,3442,3811,2901,43311,0221,999
Accrued liabilities10,7659,1291,8079537257,0265,8954,660————
Total current liabilities13,56318,1772,8141,3483,24810,5308,7857,5976,2475,92114,3296,643
Lease liability, non-current81264257649237954940926712000590
Total liabilities15,44418,8263,3971,8483,62711,0799,2347,9046,4075,93314,3417,245
Accumulated deficit(190,517)(218,474)(226,900)(232,261)(235,953)(154,724)(170,649)(186,039)(200,738)(214,241)(229,398)(244,744)
Total stockholders' equity114,94488,61081,24276,86974,018103,82890,64878,16666,42856,184184,353172,108
Total liabilities and equity130,388107,43684,63978,71777,645114,90799,88286,07072,83562,117198,694179,353
Common shares outstanding (cover page) thousands of shares33,31233,42133,42133,4293,344————13,67440,39540,496
  • † Share count changed about 1/10 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 4x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 3x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (OKUR's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024†Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025†Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Net income (loss)(19,196)(23,554)*(8,426)(5,361)(3,692)(17,442)(15,925)(15,390)(14,699)(13,503)(15,157)(15,346)
Stock-based compensation1,429*1,319*1,078989*826*1,637*2,7452,908*2,961*3,019*2,7803,049*
Depreciation and amortization43*44*16115114419*118117108104*10487*
Net cash from operating activities(18,767)*(19,753)*(21,014)(6,807)*(2,281)*(21,015)*(14,005)(13,274)*(13,037)*(11,512)*(12,938)(10,354)*
Purchases of property and equipment19*25*9(7)*0*50*1813*6*9*53*
Net cash from investing activities21,250*39,776*13,75722,491*25,000*(45,375)*(18)(13)*(6)*(9)*(5)(9,870)*
Share repurchases—year only——————————
Net cash from financing activities173*(4,128)*10(99)*2,000*114,218*(77)0*0*240*145,999(5,380)*
Net change in cash2,656*15,895*(7,257)15,595*24,719*47,828*(14,100)(13,287)*(13,043)*(11,281)*133,056(25,604)*
  • † Share count changed about 1/10 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 4x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 3x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
OnKure Therapeutics166,502not reported(10,354)*40.5M17.0 quarters 10-QJun 30, 2026
Champions Oncology4,35815,232(492)13.9M8.0 quarters 10-QJul 31, 2026
Rockwell Medical10,519not reported2,080*4.0M— 10-QJun 30, 2026
Outlook Therapeutics11,242not reported(21,011)*243.4M0.5 quarters 10-QJun 30, 2026
Cumberland Pharmaceuticals3,862166169*15.0M— 10-QJun 30, 2026
ProMIS Neurosciences53,429not reported(10,385)*9.0M5.1 quarters 10-QJun 30, 2026
Tempest Therapeutics779not reported(2,779)*16.0M0.3 quarters 10-QJun 30, 2026
Palatin Technologies7,492301*(2,690)*1.8M2.8 quarters 10-KJun 30, 2026
Scynexis10,487235(14,885)*9.9M3.6 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.